Back to Webinars

The Current Landscape of Insurance Reimbursement for Genetic Testing

Wednesday, October 1, 2025
4:00am PDT
1 hour
C.E.U.: 1 Category 1 Contact Hour
P.A.C.E.: 1 Unit

This presentation will summarize the current landscape of insurance coverage for genetic testing across diverse areas such as cardiology, oncology, neurology and rare disease exome sequencing, pointing out commonalities and differences between major payors. It will also highlight specific “pain point” requirements for some payors, and provide tips for increasing the likelihood that your patient will obtain coverage.

Level of instruction: intermediate 

Explore Our Tests Patient Billing Billing CARE  

60a52f8d96a23842297586
Robert Pilarski
Medical Affairs Director at Ambry Genetics
Robert Pilarski is Medical Affairs Director at Ambry Genetics, working on aligning payer policies and national genetic testing guidelines and overseeing medical necessity review processes. Prior to this he was a licensed and board-certified genetic counselor and Professor of Clinical Internal Medicine at the Wexner Medical Center and James Comprehensive Cancer Center at The Ohio State University. […]

Robert Pilarski is Medical Affairs Director at Ambry Genetics, working on aligning payer policies and national genetic testing guidelines and overseeing medical necessity review processes. Prior to this he was a licensed and board-certified genetic counselor and Professor of Clinical Internal Medicine at the Wexner Medical Center and James Comprehensive Cancer Center at The Ohio State University. He has over 90 publications in medical and scientific journals. He has presented regularly at national and regional conferences and has served as an ad hoc review for numerous medical and genetics journals. Mr. Pilarski was a past board member of the National Society of Genetic Counselors, and co-founder and past president of its Cancer Genetics Special Interest Group. Until joining Ambry Genetics he was the vice-chair of the National Comprehensive Cancer Network’s guidelines panel on Genetic/Familial High-Risk Assessment: Breast and Ovarian Cancers, which set testing and management guidelines for individuals at risk for hereditary breast and ovarian cancers.